Fig. 1: Effects of S63845 and imatinib administered as single drug or in combination on the viability of K562 and JURL-MK1 cells. | Cell Death & Disease

Fig. 1: Effects of S63845 and imatinib administered as single drug or in combination on the viability of K562 and JURL-MK1 cells.

From: Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells

Fig. 1

Relative viability (A, B) and synergy maps (C, D) of K562 (A, C) and JURL-MK1 (B, D) cells left untreated or treated for 48 h (A, C) or 32 h (B, D) with the indicated concentrations of imatinib (IM) and/or S63845, analyzed by alamarBlue (A, C) or SYTOX Green (B, D) assays. Data represent mean with standard deviation derived from three technical replicates. Experiments were performed at least twice with similar results.

Back to article page